Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venglustat GZ/SAR402671 · 1 trial · 2 indications
Venglustat area under the plasma concentration versus time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Venglustat | EXPERIMENTAL | Single dose of Venglustat is given, orally under fasting conditions |
| Name | Type | Description |
|---|---|---|
| Venglustat GZ/SAR402671 | DRUG | Pharmaceutical form: Hard Capsule Route of administration: Oral |
Inclusion criteria: For all Subjects: * Male and/or female subjects, between 18 and 79 years of age, inclusive. * Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, body mass index between 18.0 and 34.9 kg/m2, inclusive * Normal electroc...
Venglustat GZ/SAR402671 is an investigational small molecule developed by Sanofi for autosomal dominant polycystic kidney disease, a nephrology condition. It is a UGCG inhibitor and has been studied in a Phase 1 clinical trial. It is not an approved therapy and remains in clinical development.
Venglustat GZ/SAR402671 has been studied in autosomal dominant polycystic kidney disease, a genetic kidney disorder. Its clinical evaluation to date is limited to a Phase 1 trial that enrolled 24 participants, including healthy volunteers, in the United States. It is investigational and has no approved use in this indication.
Venglustat GZ/SAR402671 targets UGCG, also known as UDP-glucose ceramide glucosyltransferase. It acts as an inhibitor of this enzyme. UGCG catalyzes the first step in glycosphingolipid synthesis, and inhibiting it reduces the production of glucosylceramide-based glycosphingolipids.
Sanofi is the developer of Venglustat GZ/SAR402671. Sanofi trades on the New York Stock Exchange under the ticker SNY. The compound is also referenced by the code SAR402671.
Venglustat GZ/SAR402671 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA for any indication.
Venglustat GZ/SAR402671 has been evaluated in one completed Phase 1 trial, NCT03687554, titled Effect of Venglustat in Patients With Renal Impairment. The study enrolled 24 participants in the United States, included healthy volunteers, and was an uncontrolled, non-randomized design without blinding.
Yes. Venglustat GZ/SAR402671 is also known as SAR402671, an internal Sanofi compound code. Both names refer to the same investigational UGCG inhibitor being studied in autosomal dominant polycystic kidney disease. Searches for either name point to the same drug candidate.